968-P: Long-Term Quantitative and Qualitative Effect of Dulaglutide in Type 2 Diabetes Patients

Abstract

Background: Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist GLP-1. Aim: The aim of the study was to investigate dulaglutide’s quantitative and qualitative long-term effects in type 2 diabetes patients with unsatisfactory glycemic control. Material and Methods: 310 patients under treatment with dulaglutide were included in the study. Parameters of glycemic control (HbA1c, Fasting Blood Glucose -FBG) and cardiovascular risk factors (weight, body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, LDL, HDL, and triglycerides) were recorded, while treatment satisfaction was evaluated with the Diabetes Treatment Satisfaction Questionnaire (DTSQ). Follow up period was 52±2 weeks with assessment of study’s parameters at 12 ±2 weeks and 24±2 weeks. All the data were collected for 254 patients. Results: Patients’ age was 60.23±10.21 years. A reduction of HbA1c was during the follow-up period. HbA1c was reduced from the baseline at the 3, 6 and 12 month monitoring times (8.0±1.31 vs. 7.0.9±0.9 vs. 6.97±1.1, vs. 6.77±0.9) p<0.0001). Bodyweight was also reduced during the same monitoring times (96.30 ±20.24 vs. 92.41±18.52 vs. 90.04±18.77, vs. 89.49±18.27, p=0.001). Statistically significant change on waist circumference (p=0.010). A statistically significant reduction was noticed on LDL (p=0.022), triglycerides (p=0.016) while the improvement on HDL was not significant (p=0.108). There was a reduction of the systolic blood pressure (p=0.088) and of the diastolic blood pressure (p=0.114). Treatment satisfaction was improved as evaluated via DTSQ on both Group A (p = 0.026) Conclusion: The long-term use of dulaglutide leads to a significant reduction of HbA1c and to significant improvement of cardiovascular risk factors from the first three months of dulaglutide’s use. All these parameters are showing a steady improvement during the first twelve months of dulaglutide’s use in type 2 diabetes with an unsatisfactory glycemic control. Disclosure A. Koutsovasilis: None. A. Sotiropoulos: None. M. Pappa: None. T. Peppas: None.